In August 2025, the first generic liraglutide for weight loss received full FDA approval and coverage for brand-name liraglutide dropped by nearly 90% following that approval
Regulating Reward Systems: These drugs affect dopamine signaling, which may help with cravings, compulsions, and anhedonia (loss of pleasure)
Clinical Evidence on Semaglutide Safety in At-Risk Populations Large randomized trials, including SUSTAIN and SELECT, tracked hypoglycemic events across thousands of semaglutide users
Treatment with broad-spectrum ABX, including ampicillin, metronidazole, neomycin, and vancomycin, dramatically increased GLP-1 levels in the serum (Fig
The estimated hazard ratio for time to first MACE was 0.86 (95% CI: 0.77, 0.96) over the median follow-up duration of 49.6 months and 49.4 months for patients randomized to RYBELSUS and placebo, respectively